Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023

SELL
$3.6 - $5.25 $88,066 - $128,430
-24,463 Reduced 6.48%
353,319 $1.54 Million
Q1 2023

May 11, 2023

BUY
$4.3 - $8.27 $217,201 - $417,734
50,512 Added 15.43%
377,782 $1.68 Million
Q4 2022

Feb 13, 2023

BUY
$5.66 - $8.42 $1.85 Million - $2.76 Million
327,270 New
327,270 $2.76 Million
Q1 2022

May 13, 2022

SELL
$5.08 - $9.81 $367,974 - $710,597
-72,436 Closed
0 $0
Q4 2021

Feb 10, 2022

BUY
$8.55 - $111.89 $366,324 - $4.79 Million
42,845 Added 144.79%
72,436 $709,000
Q3 2021

Nov 10, 2021

BUY
$76.53 - $110.43 $138,901 - $200,430
1,815 Added 6.53%
29,591 $3.13 Million
Q2 2021

Aug 10, 2021

BUY
$85.37 - $114.1 $77,601 - $103,716
909 Added 3.38%
27,776 $2.37 Million
Q1 2021

May 10, 2021

BUY
$109.73 - $153.66 $2.26 Million - $3.16 Million
20,576 Added 327.07%
26,867 $3.08 Million
Q4 2020

Feb 10, 2021

SELL
$79.58 - $152.45 $1.17 Million - $2.25 Million
-14,745 Reduced 70.09%
6,291 $881,000
Q3 2020

Nov 13, 2020

BUY
$66.43 - $90.99 $551,767 - $755,762
8,306 Added 65.25%
21,036 $1.71 Million
Q2 2020

Aug 07, 2020

BUY
$44.04 - $80.69 $560,629 - $1.03 Million
12,730 New
12,730 $915,000
Q1 2020

May 15, 2020

SELL
$44.49 - $93.39 $927,127 - $1.95 Million
-20,839 Closed
0 $0
Q4 2019

Feb 10, 2020

SELL
$66.49 - $137.73 $1.06 Million - $2.2 Million
-16,000 Reduced 43.43%
20,839 $1.99 Million
Q3 2019

Nov 14, 2019

BUY
$31.0 - $89.73 $1.14 Million - $3.31 Million
36,839 New
36,839 $2.9 Million
Q2 2019

Aug 09, 2019

SELL
$36.0 - $44.73 $1.63 Million - $2.02 Million
-45,194 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$33.79 - $51.99 $1.53 Million - $2.35 Million
45,194 New
45,194 $1.83 Million

Others Institutions Holding ALLK

About Allakos Inc.


  • Ticker ALLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,726,096
  • Market Cap $81.3M
  • Description
  • Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...
More about ALLK
Track This Portfolio

Track Rafferty Asset Management, LLC Portfolio

Follow Rafferty Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.